Furthermore, ensuring a favorable safety profile remains a significant challenge in the development of Akt-blocking agents, as previous studies have underscored the potential for side effects, such as rash, nausea, fatigue, hepatotoxicity, and hyperglycemia, associated with PI3K/Akt pathway inhibitors (Liu et al., 2019; Yu et al., 2023). This evidence concerns the gene AKT1 and Hyperglycemia.